Fungus that may have caused 'King Tut's curse' shows promise in treating cancer
A toxic fungus, once thought to have caused fatal lung infections in tomb explorers, may hold the key to powerful new cancer treatments, new research suggests.
Within months of the discovery of the tomb of King Tutankhamun in 1922, the earl who had financed the excavation and visited the "wonderful" burial site died, leading many to believe the mummy had cursed those who entered the tomb. In the 1970s, 10 of the 12 archaeologists excavating the 15th-century crypt of King Casimir IV in Poland also met a similar fate.
Analysis of Casimir's tomb revealed the presence of a fungus called Aspergillus flavus, the toxins of which are known to cause a deadly lung infection.
Now, the same fungus has shown promise as a treatment for leukaemia, according to a new study published in Nature Chemical Biology. The researcher team identified and engineered a class of molecules within the fungus, called asperigimycins, that kill leukemia cells in a laboratory setting.
"This is nature's irony at its finest," study senior author Sherry Gao, a professor of chemical and biomolecular engineering at the University of Pennsylvania, said in a statement. "The same fungus once feared for bringing death may now help save lives."
Aspergillus flavus produces spores that are able to lie dormant for centuries — including inside sealed tombs. When disturbed, the fungus can cause deadly respiratory infections, particularly in people with weakened immune systems.
Related: College student discovers psychedelic fungus that eluded LSD inventor
In their new study, the scientists examined the unique chemical compounds produced by the fungus and discovered a class of natural compounds called RiPPs (ribosomally synthesized and post-translationally modified peptides). These molecules are difficult to isolate and rarely seen in fungi, but they hold therapeutic promise due to their complex structures and bioactivity. This means they have intricate, unique shapes that can interact with biological systems in powerful ways, such as killing cancer cells.
"We found four novel asperigimycins with an unusual interlocking ring structure," lead author Qiuyue Nie, a researcher in chemical and biomolecular engineering at the University of Pennsylvania, said in the statement. "Two of them had strong anti-leukemia properties even without modification."
To enhance the drugs' effectiveness, the researchers attached lipid molecules similar to those found in royal jelly, the nutrient-rich substance that sustains queen bees. This enabled the drugs to enter cancer cells more efficiently, because lipids help drugs cross cellular membranes, which are made largely of fats themselves.
Further analysis revealed how a gene called SLC46A3 acts as a kind of molecular gateway, helping the drug escape cellular compartments and target leukemia cells directly. This discovery could aid in the delivery of other promising but hard-to-administer drugs in the future.
RELATED STORIES
—'The most critically harmful fungi to humans': How the rise of C. auris was inevitable
—Mysterious artifacts from King Tut's tomb might have been used in 'awakening Osiris' ritual
—Single gene may help explain the plague's persistence throughout human history
Unlike broad-spectrum chemotherapy agents that can damage healthy cells, asperigimycins appear to specifically disrupt leukemia cell division without affecting healthy tissues. Early tests also suggest the compounds have minimal effects on breast, liver, and lung cancer cells. According to the researchers, this selectivity is important for minimizing unwanted side effects.
In addition to asperigimycins, the team believe similar life-saving compounds may be hidden in other fungal species.
The team are planning to test asperigimycins in animal models, with the eventual goal of launching human clinical trials. And by scanning fungal genomes and exploring more strains of Aspergillus, they hope to unlock new treatments.
"The ancient world is still offering us tools for modern medicine," said Gao. "The tombs were feared for their curses, but they may become a wellspring of cures."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
First new treatment for advanced bladder cancer in decades given green light
A new treatment for advanced bladder cancer which doubles survival time has been given the green light for NHS use. Experts said the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease, saying that until now, the treatment for advanced bladder cancer had not significantly changed since the 1980s. They said there had been real 'unmet need' for patients with advanced disease, with some 29% of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30%) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5% of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.
Associated Press
5 hours ago
- Associated Press
Israel condemned at funeral in Italy for Palestinian woman who died after medevac from Gaza
Zuhri Marah Salah Mahmoud had been medevaced with what Israel had called leukemia, but Italian doctors said they found no initial evidence of that and instead found 'profound wasting' and an undiagnosed or misdiagnosed condition. She was buried in an empty corner of the cemetery in the Tuscan town of Pontasserchio, and the mayor said that part of the graveyard would from now on be reserved for Muslim faithful.
Gizmodo
8 hours ago
- Gizmodo
Stone Age People Brutalized Their Prisoners of War, New Evidence Suggests
When we think of Stone Age people, most imagine small communities living in caves, cutting into their most recent hunt with primitive tools, and imitating their environment with illustrative rock art. People during the Neolithic, however—the last stage of the Stone Age (around 9000 to 3300 BCE)—also waged wars and absolutely demolished their enemies. In a study published today in the journal Science Advances, researchers present horrific evidence suggesting that Neolithic people in northeastern France mutilated foreign invaders. Their findings might represent some of the earliest known indications of gruesome victory celebrations related to war. The international team of researchers analyzed skeletal remains and severed limbs from burial pits dating to between 4300 and 4150 BCE at two sites near Strasbourg, Achenheim and Bergheim. 'A total of 82 humans are analyzed,' they wrote in the study. Their analysis revealed 'differences between victims and nonvictims and suggest that the former were members of invading groups brutally killed, perhaps exposed and deposited in pits—together with trophies in the form of severed upper limbs—by local groups in what might be one of the earliest well-documented instances of martial victory celebrations in prehistoric Europe,' they explained. Previous research in the Upper Rhine Valley had already shown that this time period was marked by military invasions and cultural upheaval, but scientists didn't know whether the human remains at Achenheim and Bergheim were of locals or foreigners and/or prisoners of war. In addition to the severed upper limbs, the researchers also identified injuries such as skull fractures that had not healed. The team, including Valladolid University's Teresa Fernandez-Crespo, suggests these victims met violent ends during war. The individuals without these sorts of unhealed injuries, on the other hand, likely received a regular burial. To investigate the differences between those who were brutally killed and those who weren't, Fernandez-Crespo and her colleagues conducted isotopic analyses. By identifying ratios of isotopes—variants of the same element—in the remains, they discovered that, while the non-victims were locals, the victims of war violence came from other regions. According to the researchers, this indicates that the victims were likely invaders killed by locals. 'In view of their demise, it is probable that the identities of these victims can be attributed to socially remote, nonlocal enemies that became trophies or captives during battles or raids and that may have been considered by their captors as not properly 'human' and hence warranting such treatment,' the researchers explained. For once, the term 'overkill' applies literally.
